Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

SELARSDI gains FDA interchangeability with Stelara, enhancing access to affordable treatments for psoriatic arthritis, psoriasis, Crohn's, and ulcerative colitis.

Ustekinumab-aekn Now Interchangeable With Reference for PsA, PsO, CD, UC

Upadacitinib joins tocilizumab as the second therapy to be approved for treating GCA.

FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis

These data suggest promise for dietary interventions and anti-obesity therapies such as incretin-based weight loss medicines for those with psoriatic arthritis (PsA).

Dietary Interventions, Resulting Weight Loss Improve Symptoms of Psoriatic Arthritis

3-year interim analysis of the SERENA study confirmed the safety of secukinumab to treat psoriatic arthritis and ankylosing spondylitis.

Secukinumab Retention, Efficacy, Safety Confirmed by Recent Interim Analysis

Findings suggest MetS is linked to greater levels of pain catastrophizing in psoriatic arthritis, highlighting the need for multidisciplinary care.

Metabolic Syndrome Worsens Pain Catastrophizing in Psoriatic Arthritis

Tumor necrosis factor-α inhibitors are suggested as the optimal treatment for both joint and skin symptoms.

TNF-α, IL-17A Inhibitors Achieve Superior Arthritis, Skin Responses in PsA

Ten percent of effector genes identified express proteins targeted by approved drugs across disease fields.

Largest Osteoarthritis GWAS to Date Highlights Opportunities for Drug Repurposing and Novel Targets

Investigators call for faster diagnosis and better treatment for psoriatic arthritis to avoid unnecessary complication and suffering.

Study Finds Diagnostic Delay, Less Intensive Therapy Use in PsA than RA

Anti-IL-17 medications meant to treat psoriasis and psoriatic arthritis may inadvertently harm gastrointestinal tract.

IL-17 Inhibitors May Raise Inflammatory Bowel Disease Risk, New Study Suggests

hsCRP may be a more accessible and reliable method of indicating inflammation, a known precursor to PsA.

High Sensitivity C-Reactive Protein May Predict Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.